Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents
Status:
Not yet recruiting
Trial end date:
2021-03-02
Target enrollment:
Participant gender:
Summary
Intestinal microflora refers to the trillions of microorganisms living in our gut, which is
considered as an independent endocrine organ of human body. Intestinal microbiota plays a
very important role in human health. The composition of human intestinal microbiota is
affected by a variety of factors, including age, living region, eating habits, nutrition,
probiotics, antibiotics and so on. It is found that the imbalance of intestinal microbiota is
closely related to the occurrence and development of metabolic diseases including type 2
diabetes mellitus (T2DM). There are great differences in the structure and function of
intestinal microbiota between healthy people and T2DM patients, and recently changes of
intestinal microbiota have been observed in pre-diabetes. In recent years, it has been found
that some commonly used hypoglycemic drugs may regulate and improve the imbalance of
intestinal flora of T2DM patients, including metformin, α - glucosidase inhibitor, and
Glucagon-like peptide-1(GLP-1) receptor agonist, which have a positive impact on the short
chain fatty acid (SCFAs) producing bacteria. However, on the one hand, subjects of those
studies were mostly western population and there were just a few studies on the influence of
anti-diabetic drug on human gut microbiota in Chinese population, on the other hand, the
study of influence of Dipeptidyl peptidase-4(DPP-4) inhibitors, sulfonylureas,
sodium-dependent glucose transporters-2(SGLT-2) inhibitors or thiazolidinediones on
intestinal microbiota is rare or even absent. This study aims to explore the effect of
different hypoglycemic drugs on intestinal flora and find the potential intestinal target of
drug action in Chinese population.